查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1547418

全球单株抗体市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Monoclonal Antibody Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

全球单株抗体市场需求预计将从2023年的2,362.3亿美元达到2032年近2,691.5亿美元的市场规模，2024-2032年研究期间复合年增长率为1.46%。

单株抗体（mAb 或 moAb）是实验室製造的蛋白质类型，可以与体内的物质结合。它们是由单一 B 细胞克隆产生的相同免疫球蛋白。单株抗体可用于治疗多种疾病，可单独使用，也可携带药物、毒素或放射性物质。单株抗体有许多品种，其製备方法也不同，它们根据嵌合抗体、鼠源抗体、人源化抗体和人源抗体的製备方式来命名。单株抗体可辨识单一抗原上的独特抗原决定位或结合位点。它们在免疫系统中的作用类似人类抗体。

市场动态

单株抗体（mAb 或 moAb）已成为生物化学、分子生物学和医学的重要工具。慢性病和癌症发病率的上升、监管部门批准的增加、疗法的推出以及研发的不断增长主要推动了全球单株抗体市场。慢性病和癌症是全世界死亡的主要原因。根据世界卫生组织估计，全球约三分之二的死亡是由慢性病造成的。 2020年，癌症导致近千万人死亡。随着 COVID-19 大流行的兴起，单株抗体引起了人们的关注。它们已经取得了进展，可以得到更广泛的使用。单株抗体为製药业和治疗 COVID-19 大流行提供了许多好处，包括生产时间短、成本低、高度稳定且耐受 pH 或缓衝液变化、高亲和力以及对微小抗原变化的耐受性。单株抗体被认为是治疗 COVID-19 患者的一种有前途的方法。正在进行强有力的研究，以利用它来治疗 COVID-19。然而，与单株抗体相关的较高成本、严格的监管措施、对单株抗体的认识较低以及缺乏研究可能会阻碍市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球单株抗体市场的各个细分市场进行了包容性评估。单株抗体产业的成长和趋势为本研究提供了整体方法。

市场区隔

单株抗体市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按来源

  • 鼠类
  • 嵌合体
  • 人性化
  • 人类

按产量

  • 体内
  • 体外

按申请

  • 肿瘤学
  • 自体免疫疾病
  • 传染病
  • 神经系统疾病
  • 其他的

按最终用途

  • 医院
  • 专科中心
  • 其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲单株抗体市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。单株抗体市场的主要参与者包括诺华公司、辉瑞公司、葛兰素史克公司、安进公司、默克公司、第一三共有限公司、雅培实验室、阿斯特捷利康公司、礼来公司、强生服务公司Inc.、拜耳股份公司、Bristol Myers Squibb、F. Hoffman-La Roche Ltd.、Viatris Inc.、Biogen Inc.、Thermo Fisher Scientific Inc.、Novo Nordisk A/S、Sanofi SA、Merck KGaA。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：单株抗体 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按来源分類的市场吸引力分析
    • 按产量分析市场吸引力
    • 市场吸引力分析：依应用分类
    • 按最终用途分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球单株抗体市场分析：依来源分类

  • 按来源概述
  • 按来源分類的历史和预测资料分析
  • 鼠类
  • 嵌合体
  • 人性化
  • 人类

第 6 章：全球单株抗体市场分析：依产量分类

  • 按生产概览
  • 按生产进行的历史和预测数据分析
  • 体内
  • 体外

第 7 章：全球单株抗体市场分析：依应用分类

  • 概述：按应用
  • 历史与预测资料分析：按应用分类
  • 肿瘤学
  • 自体免疫疾病
  • 传染病
  • 神经系统疾病
  • 其他的

第 8 章：全球单株抗体市场分析：依最终用途分类

  • 按最终用途分类的概述
  • 按最终用途分类的历史和预测资料分析
  • 医院
  • 专科中心
  • 其他的

第 9 章：全球单株抗体市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 10 章：单株抗体公司的竞争格局

  • 单株抗体市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 11 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Novartis AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • GlaxoSmithKline Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Amgen Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Merck & Co. Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Daiichi Sankyo Company
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Limited
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Abbott Laboratories
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • AstraZeneca Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Eli Lilly And Company
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Johnson & Johnson Services Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bayer AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bristol Myers Squibb
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • F. Hoffman-La Roche Ltd.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Viatris Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Biogen Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Thermo Fisher Scientific Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Novo Nordisk A/S
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sanofi SA
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Merck KGaA
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR11215463

The global demand for Monoclonal Antibody Market is presumed to reach the market size of nearly USD 269.15 Billion by 2032 from USD 236.23 Billion in 2023 with a CAGR of 1.46% under the study period 2024-2032.

Monoclonal antibodies (mAb or moAb) are a protein type made in the laboratory that can bind to substances in the body. They are identical immunoglobulins generated from a single B-cell clone. Monoclonal antibodies are employed to treat many diseases and can be used alone or carry drugs, toxins, or radioactive substances. There are many varieties of monoclonal antibodies and different ways of making them, and they are named based on how they are made of chimeric, murine, humanized, and human. Monoclonal antibodies recognize unique epitopes, or binding sites, on a single antigen. They act like human antibodies in the immune system.

MARKET DYNAMICS

Monoclonal antibodies (mAb or moAb) have become an important tool in biochemistry, molecular biology, and medicine. Rising incidence of chronic diseases and cancer, increasing regulatory approvals, the launch of therapies, and growing R&D primarily drive the global monoclonal antibody market. Chronic diseases and cancer are the leading cause of death worldwide. According to the World Health Organization estimates, chronic diseases are responsible for around two-thirds of all deaths worldwide. In 2020, cancer caused the death of nearly 10 million people. Monoclonal antibodies have gained attention with the rise of the COVID-19 pandemic. They have progressed to allow more widespread use. Monoclonal antibodies offer many benefits to the pharmaceutical industry and treat the COVID-19 pandemic, including short production time, low cost, highly stable and tolerant of pH or buffer changes, high affinity, and tolerance of minor antigen changes. Monoclonal antibodies are identified as a promising approach for treating COVID-19 patients. Robust research is being carried out to use it to treat COVID-19. However, higher costs associated with a monoclonal antibody, strict regulatory measures, low awareness about monoclonal antibody, and lack of research is likely to hamper the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Monoclonal Antibody. The growth and trends of Monoclonal Antibody industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Monoclonal Antibody market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Source

  • Murine
  • Chimeric
  • Humanized
  • Human

By Production

  • In Vivo
  • In Vitro

By Application

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Neurological Diseases
  • Others

By End-use

  • Hospitals
  • Specialty Centers
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Monoclonal Antibody market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Monoclonal Antibody market include Novartis AG, Pfizer Inc, GlaxoSmithKline Plc, Amgen Inc., Merck & Co. Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca Plc, Eli Lilly And Company, Johnson & Johnson Services Inc., Bayer AG, Bristol Myers Squibb, F. Hoffman-La Roche Ltd., Viatris Inc., Biogen Inc., Thermo Fisher Scientific Inc., Novo Nordisk A/S, Sanofi S.A., Merck KGaA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. MONOCLONAL ANTIBODY - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Source
    • 3.7.2 Market Attractiveness Analysis By Production
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By End-use
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY SOURCE

  • 5.1. Overview By Source
  • 5.2. Historical and Forecast Data Analysis By Source
  • 5.3. Murine Historic and Forecast Sales By Regions
  • 5.4. Chimeric Historic and Forecast Sales By Regions
  • 5.5. Humanized Historic and Forecast Sales By Regions
  • 5.6. Human Historic and Forecast Sales By Regions

6. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY PRODUCTION

  • 6.1. Overview By Production
  • 6.2. Historical and Forecast Data Analysis By Production
  • 6.3. In Vivo Historic and Forecast Sales By Regions
  • 6.4. In Vitro Historic and Forecast Sales By Regions

7. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY APPLICATION

  • 7.1. Overview By Application
  • 7.2. Historical and Forecast Data Analysis By Application
  • 7.3. Oncology Historic and Forecast Sales By Regions
  • 7.4. Autoimmune Diseases Historic and Forecast Sales By Regions
  • 7.5. Infectious Diseases Historic and Forecast Sales By Regions
  • 7.6. Neurological Diseases Historic and Forecast Sales By Regions
  • 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY END-USE

  • 8.1. Overview By End-use
  • 8.2. Historical and Forecast Data Analysis By End-use
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Specialty Centers Historic and Forecast Sales By Regions
  • 8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE MONOCLONAL ANTIBODY COMPANIES

  • 10.1. Monoclonal Antibody Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF MONOCLONAL ANTIBODY INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Novartis AG
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Pfizer Inc
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. GlaxoSmithKline Plc
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Amgen Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Merck & Co. Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Daiichi Sankyo Company
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Limited
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Abbott Laboratories
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. AstraZeneca Plc
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Eli Lilly And Company
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Johnson & Johnson Services Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Bayer AG
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. Bristol Myers Squibb
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments
  • 11.16. F. Hoffman-La Roche Ltd.
    • 11.16.1 Company Overview
    • 11.16.2 Company Revenue
    • 11.16.3 Products
    • 11.16.4 Recent Developments
  • 11.17. Viatris Inc.
    • 11.17.1 Company Overview
    • 11.17.2 Company Revenue
    • 11.17.3 Products
    • 11.17.4 Recent Developments
  • 11.18. Biogen Inc.
    • 11.18.1 Company Overview
    • 11.18.2 Company Revenue
    • 11.18.3 Products
    • 11.18.4 Recent Developments
  • 11.19. Thermo Fisher Scientific Inc.
    • 11.19.1 Company Overview
    • 11.19.2 Company Revenue
    • 11.19.3 Products
    • 11.19.4 Recent Developments
  • 11.20. Novo Nordisk A/S
    • 11.20.1 Company Overview
    • 11.20.2 Company Revenue
    • 11.20.3 Products
    • 11.20.4 Recent Developments
  • 11.21. Sanofi S.A.
    • 11.21.1 Company Overview
    • 11.21.2 Company Revenue
    • 11.21.3 Products
    • 11.21.4 Recent Developments
  • 11.22. Merck KGaA
    • 11.22.1 Company Overview
    • 11.22.2 Company Revenue
    • 11.22.3 Products
    • 11.22.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Source (USD MN)
  • Murine Market Sales By Geography (USD MN)
  • Chimeric Market Sales By Geography (USD MN)
  • Humanized Market Sales By Geography (USD MN)
  • Human Market Sales By Geography (USD MN)
  • Analysis By Production (USD MN)
  • In Vivo Market Sales By Geography (USD MN)
  • In Vitro Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Autoimmune Diseases Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Neurological Diseases Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Monoclonal Antibody Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Monoclonal Antibody Report
  • Market Research Process
  • Market Research Methodology
  • Global Monoclonal Antibody Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Source
  • Market Attractiveness Analysis By Production
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By End-use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Source (USD MN)
  • Murine Market Sales By Geography (USD MN)
  • Chimeric Market Sales By Geography (USD MN)
  • Humanized Market Sales By Geography (USD MN)
  • Human Market Sales By Geography (USD MN)
  • Global Market Analysis By Production (USD MN)
  • In Vivo Market Sales By Geography (USD MN)
  • In Vitro Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Autoimmune Diseases Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Neurological Diseases Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.